查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1609120

重症肌無力治療市場：按類型、最終用戶分類 - 2025-2030 年全球預測

Myasthenia Gravis Treatment Market by Type (Medication, Surgery), End-User (Clinics, Hospitals) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

重症肌無力治療市場2023年估值為19.3億美元，預計到2024年將達到20億美元，複合年成長率為5.21%，預計到2030年將達到27.6億美元。

在盛行率增加、診斷技術改進和治療方法進步的推動下，重症肌無力 (MG) 治療市場有望實現動態和顯著成長。重症肌無力是一種慢性自體免疫神經肌肉疾病，其特徵是波動性肌肉無力和疲勞。治療的需要源於改善病人的生活品質和預防危及生命的情況的需要。治療通常涉及免疫抑制劑、單株抗體和乙醯膽鹼酯酶抑制劑，並應用於醫院、神經科診所和研究機構。最終用戶包括希望在這一領域進行創新的醫療保健提供者、患者和製藥公司。

主要市場統計
基準年[2023] 19.3億美元
預計年份 [2024] 20億美元
預測年份 [2030] 27.6億美元
複合年成長率（%） 5.21%

成長是由幾個關鍵因素推動的，包括醫療保健支出的增加、生物技術的進步以及醫療保健專業人員和患者對罕見神經系統疾病的認知提高。新療法的進入，例如艾加替莫德和新型生物製藥，帶來了巨大的潛在機會。對於希望利用這一前景的公司來說，投資於針對遺傳標記的藥物發現和個人化醫療將是有益的。此外，與研究機構合作進行臨床試驗可能會促進新治療方法的推出。

然而，其局限性包括治療成本高、長期免疫抑制治療的潛在副作用以及針對重症肌無力等罕見疾病的大規模臨床試驗的複雜性。此外，嚴格的監管協議可能會阻礙新藥的快速核准。

創新應專注於開發副作用最小的標靶治療、利用人工智慧進行藥物發現以及提高患者對數位健康解決方案的依從性。用於早期診斷和進展追蹤的生物標記研究可以大大增強治療策略。 MG 的治療是一個利基市場，是專業化的，需要對病理學有深入的了解並遵守法規。總體而言，市場預計將實現穩健成長，但必須仔細克服獨特的挑戰，以實現永續的業務成長。

市場動態：快速發展的重症肌無力治療市場的關鍵市場洞察

重症肌無力治療市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 世界老年人口的增加
    • 重症肌無力導致眼睛腫脹的病例增加
    • 治療臨床試驗的增加
  • 市場限制因素
    • 治療高成本
  • 市場機會
    • 改善醫療基礎設施
    • 藥物開發管道研究迅速增加
  • 市場挑戰
    • 與藥物相關的副作用

波特的五力策略工具駕馭重症肌無力治療市場

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解重症肌無力治療市場的外在影響

外部宏觀環境因素在塑造重症肌無力治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解重症肌無力治療市場的競爭狀況

對重症肌無力治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣重症肌無力治療市場供應商的績效評估

FPNV 定位矩陣是評估重症肌無力治療市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製重症肌無力治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對重症肌無力治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地人口老化仍在持續
      • 重症肌無力導致眼睛腫脹的病例增加
      • 治療臨床試驗的增加
    • 抑制因素
      • 治療費用高
    • 機會
      • 改善醫療基礎設施
      • 藥物開發平臺研究數量快速增加
    • 任務
      • 與藥物相關的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章重症肌無力治療市場：依類型

  • 藥物治療
  • 外科手術

第7章重症肌無力治療市場：依最終使用者分類

  • 診所
  • 醫院

第8章美洲重症肌無力治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區重症肌無力治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲重症肌無力治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Alexion Pharmaceutical Inc.
  • Argenx
  • Avadel Pharmaceuticals, PLC
  • Bausch Health Companies Inc.
  • Catalyst Pharmaceuticals Inc.
  • CSL Behring AG
  • F.Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Mitsubishi Tanabe Pharma Corporation
  • Pfizer, Inc.
  • Sandoz Inc. by Novartis AG
  • Sun Pharmaceuticals Industries
  • Taj Pharmaceuticals Ltd.
  • Takeda Pharmaceuticals Company Limited
  • Troikaa Pharmaceuticals Ltd.
Product Code: MRR-0A609A26A9B8

The Myasthenia Gravis Treatment Market was valued at USD 1.93 billion in 2023, expected to reach USD 2.00 billion in 2024, and is projected to grow at a CAGR of 5.21%, to USD 2.76 billion by 2030.

The market for Myasthenia Gravis (MG) treatments is dynamic and poised for substantial growth, driven by increasing prevalence rates, enhanced diagnostic techniques, and advancements in therapeutic approaches. Myasthenia Gravis is a chronic autoimmune neuromuscular disease characterized by fluctuating muscle weakness and fatigue. The necessity for treatments stems from the need to enhance patient quality of life and prevent life-threatening conditions. Treatment typically involves immunosuppressive drugs, monoclonal antibodies, and acetylcholinesterase inhibitors, with applications in hospitals, specialized neurology clinics, and research settings. End-users include healthcare providers, patients, and pharmaceutical companies seeking to innovate in this sector.

KEY MARKET STATISTICS
Base Year [2023] USD 1.93 billion
Estimated Year [2024] USD 2.00 billion
Forecast Year [2030] USD 2.76 billion
CAGR (%) 5.21%

Growth is influenced by several key factors, including increased healthcare expenditure, advancements in biotechnology, and heightened awareness among healthcare professionals and patients regarding rare neurological disorders. The entry of novel therapies such as efgartigimod and novel biologics presents significant potential opportunities. For businesses looking to capitalize on these prospects, investing in drug discovery and personalized medicine tailored to genetic markers could prove beneficial. Moreover, partnerships with research institutions for clinical trials could expedite the introduction of new therapies.

However, the market faces limitations such as high treatment costs, potential side effects of long-term immunosuppressive therapies, and the complexity of conducting large-scale clinical trials for an orphan disease like MG. Additionally, stringent regulatory protocols can hinder the fast-track approval of new drugs.

Innovation should focus on developing targeted therapies with minimal side effects, leveraging artificial intelligence for drug discovery, and enhancing patient adherence through digital health solutions. Research into biomarkers for early diagnosis and progression tracking can significantly enhance treatment regimes. As a niche market, the nature of MG treatment is specialized, requiring a deep understanding of neurological pathophysiology and regulatory compliance. Overall, the market presents robust growth prospects but requires careful navigation through its inherent challenges to achieve sustainable business growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Myasthenia Gravis Treatment Market

The Myasthenia Gravis Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing geriatric population across the globe
    • Increasing cases of swollen eyes due to Myasthenia Gravis
    • Rising clinical trials for treatment
  • Market Restraints
    • High cost associated with the treatment
  • Market Opportunities
    • Improving healthcare infrastructure
    • Upsurge in the number of pipeline studies for drug development
  • Market Challenges
    • Side effects associated with drugs

Porter's Five Forces: A Strategic Tool for Navigating the Myasthenia Gravis Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Myasthenia Gravis Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Myasthenia Gravis Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Myasthenia Gravis Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Myasthenia Gravis Treatment Market

A detailed market share analysis in the Myasthenia Gravis Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Myasthenia Gravis Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Myasthenia Gravis Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Myasthenia Gravis Treatment Market

A strategic analysis of the Myasthenia Gravis Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Myasthenia Gravis Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alexion Pharmaceutical Inc., Argenx, Avadel Pharmaceuticals, PLC, Bausch Health Companies Inc., Catalyst Pharmaceuticals Inc., CSL Behring AG, F.Hoffmann-La Roche AG, GlaxoSmithKline PLC, Mitsubishi Tanabe Pharma Corporation, Pfizer, Inc., Sandoz Inc. by Novartis AG, Sun Pharmaceuticals Industries, Taj Pharmaceuticals Ltd., Takeda Pharmaceuticals Company Limited, and Troikaa Pharmaceuticals Ltd..

Market Segmentation & Coverage

This research report categorizes the Myasthenia Gravis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Medication and Surgery.
  • Based on End-User, market is studied across Clinics and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing geriatric population across the globe
      • 5.1.1.2. Increasing cases of swollen eyes due to Myasthenia Gravis
      • 5.1.1.3. Rising clinical trials for treatment
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Improving healthcare infrastructure
      • 5.1.3.2. Upsurge in the number of pipeline studies for drug development
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Myasthenia Gravis Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Medication
  • 6.3. Surgery

7. Myasthenia Gravis Treatment Market, by End-User

  • 7.1. Introduction
  • 7.2. Clinics
  • 7.3. Hospitals

8. Americas Myasthenia Gravis Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Myasthenia Gravis Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Myasthenia Gravis Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alexion Pharmaceutical Inc.
  • 3. Argenx
  • 4. Avadel Pharmaceuticals, PLC
  • 5. Bausch Health Companies Inc.
  • 6. Catalyst Pharmaceuticals Inc.
  • 7. CSL Behring AG
  • 8. F.Hoffmann-La Roche AG
  • 9. GlaxoSmithKline PLC
  • 10. Mitsubishi Tanabe Pharma Corporation
  • 11. Pfizer, Inc.
  • 12. Sandoz Inc. by Novartis AG
  • 13. Sun Pharmaceuticals Industries
  • 14. Taj Pharmaceuticals Ltd.
  • 15. Takeda Pharmaceuticals Company Limited
  • 16. Troikaa Pharmaceuticals Ltd.

LIST OF FIGURES

  • FIGURE 1. MYASTHENIA GRAVIS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. MYASTHENIA GRAVIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. MYASTHENIA GRAVIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MYASTHENIA GRAVIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MYASTHENIA GRAVIS TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 16. ARGENTINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. AUSTRALIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. INDIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. INDONESIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. MALAYSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. PHILIPPINES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. SINGAPORE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. SOUTH KOREA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. TAIWAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. THAILAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. VIETNAM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. DENMARK MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. EGYPT MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. FINLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. ISRAEL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. NETHERLANDS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. NIGERIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. NORWAY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. POLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. QATAR MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SAUDI ARABIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SWEDEN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. SWITZERLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. TURKEY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED ARAB EMIRATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. MYASTHENIA GRAVIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 100. MYASTHENIA GRAVIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023